Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-07

Study Completion Date

2022-07-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates clinical responses and cost-effectiveness of using etanercept (ETN) and conventional synthetic Disease modifying anti-rheumatic drugs (csDMARDs) with treat-to-target strategy in ankylosing spondylitis patients. Half of participants will be used treat-to-target strategy with ETN and csDMARDs, while the others will be used conventional therapy scheme with ETN only.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis

NCT03880968

Spondylitis, Ankylosing

COMPLETED

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

NCT01578850

Rheumatoid Arthritis

COMPLETED PHASE4

A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis

NCT02809781

Spondylitis Spondylitis, Ankylosing Ankylosis +6 more

UNKNOWN PHASE2/PHASE3

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

NCT01411215

Rheumatoid Arthritis Ankylosing Spondylitis

TERMINATED

Etanercept (Enbrel) in Ankylosing Spondylitis

NCT01289743

Ankylosing Spondylitis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The tumor necrosis factor inhibitors(TNFi) like etanercept(ETN) has been always recommended as the primary treatment option for active AS. But when sustained applied in daily clinical practices, it is unaffordable for patients in developing countries in most cases due to the high expense of TNFi. On this ground, this study proposes a new scheme dividing AS treatment into relatively active phase and relatively stable phase, and sequentially introducing TNFi and conventional synthetic Disease modifying anti-rheumatic drugs (csDMARDs) in each phase respectively. Taking full advantages of the rapid and precise efficacy of TNFi when short-term application in active AS and then csDMARDs combination was prescribed to maintain the remission cause by TNFi. Drug regimes are adjusted according to the different responses of individual patient based on treat-to-target strategy. TNFi is reintroduced if there is a reactive tendency and then switching to csDMARDs again when patients are in remission. Thus, the continuous low activity or remission of AS may be promising through this treating management and the treatment cost will reduce for csDMARDs partially replace TNFi in the management of relatively stable phase.

This study is designed as a prospective randomized, positive controlled, 48-week clinical trial, involving 100 patients with active ankylosing spondylitis. All enrolled patients will randomly assign to 2 groups for the comparison of the clinical responses and cost-effectiveness of our treatment scheme with that of the conventional therapy scheme of TNFi (etanercept). Multiple clinical indexes will be measured to evaluate the therapeutic effect, including Patient's Global Assessment, BASDAI and ASDAS-CRP for disease activity, BASFI for functional state, EQ-5D and SF-36 for quality-of-life assessment, SPARCC and SPARCC Sacroiliac Joint Structural Score (SSS) for sacroiliac joint invasion. We expect to assess the feasibility of our new treatment scheme in AS disease controlling and cost-effectiveness improving through this one-year follow-up study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankylosing Spondylitis Spondyloarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

All enrolled participants will be randomly divided into 2 groups evenly. Participants in Group 1 will be treated with etanercept and conventional synthetic DMARDs based on treat-to-target strategy, while the others in Group 2 will be treated with conventional therapy scheme using etanercept only.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1. Experimental

Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.

Sulfasalazine

Intervention Type DRUG

Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.

Hydroxychloroquine

Intervention Type DRUG

Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.

Etanercept (50mg per week, for 4 weeks)

Intervention Type DRUG

Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.

Etanercept (50mg per week, for 2 weeks)

Intervention Type DRUG

Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.

Group 2. Positive Control

Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.

Group Type ACTIVE_COMPARATOR

Etanercept (50mg per week)

Intervention Type DRUG

Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methotrexate

Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.

Intervention Type DRUG

Sulfasalazine

Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.

Intervention Type DRUG

Hydroxychloroquine

Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.

Intervention Type DRUG

Etanercept (50mg per week, for 4 weeks)

Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.

Intervention Type DRUG

Etanercept (50mg per week, for 2 weeks)

Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.

Intervention Type DRUG

Etanercept (50mg per week)

Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anbainuo® Anbainuo® Anbainuo®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Capability to understand and voluntarily give written informed consent that is signed and dated, before any specific procedure of the protocol is performed.
* Patients 18 to 45 years of age.
* Proven AS according to the modified New York criteria.
* Acute phase of disease with ASDAS score ≥1.3.
* Ability to reconstitute the drug and self-inject it or have a person who can do so.
* Ability to store injectable test article at 2º to 8º C.

Exclusion Criteria

* Patients with a history of active tuberculosis, hepatitis, gastrointestinal hemorrhage, tumors, infectious diseases or combined with other rheumaimmune systemic diseases or osteoarthritis diseases.
* Pregnancy/lactation.
* Receipt of any live (attenuated) vaccines within 4 weeks before the screening visit.
* Significant concurrent medical diseases including uncompensated congestive heart failure (NYHA III-IV), myocardial infarction within 12 months, stable or unstable angina pectoris, uncontrolled hypertension, severe pulmonary disease, history of human immunodeficiency virus (HIV) infection.
* Participation in trials of other investigational medications within 30 days of entering the study.
* Clinical examination showing significant abnormalities of clinical relevance.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No